Interim Guidance for Zika Virus Testing of Urine - United States, 2016

Details

• Journal Article:
  MMWR. Morbidity and Mortality Weekly Report
• Corporate Authors:
  Centers for Disease Control and Prevention (U.S.)
• Description:
  On May 10, 2016, this report was posted online as an MMWR Early Release.
  
  Diagnostic tTesting for Zika Virus infection can be accomplished using molecular and serologic Methods. Real-time reverse transcription-polymerase chain reaction (rRT-PCR) is the preferred test for Zika Virus infection because it can be performed rapidly and is highly specific (1,2). However, in most patients, Zika Virus RNA is unlikely to be detected in serum after the first week of illness (2,3). Recent reports using adaptations of previously published Methods (2,4) suggest that Zika Virus RNA can be detected in urine for at least 2 weeks after onset of symptoms (3,5-7). Currently, the CDC Trioplex rRT-PCR assay is the only diagnostic tool authorized by the Food and Drug Administration for Zika Virus tTesting of urine (1). Other laboratory-developed tests will need in-house validations to adequately characterize the performance of the assay and meet Clinical Laboratory Improvement Amendments requirements. Further investigation is needed to determine the sensitivity and utility of Zika Virus rRT-PCR on urine specimens collected ≥14 days after onset of symptoms.
  
  On the basis of the newly available data, CDC recommends that Zika Virus rRT-PCR be performed on urine collected <14 days after onset of symptoms in patients with suspected Zika Virus disease. Zika Virus rRT-PCR tTesting of urine should be performed in conjunction with serum tTesting if using specimens collected <7 days after symptom onset (8). A positive result in either specimen type provides evidence of Zika Virus infection. Procedures for the collection and submission of body fluids, including urine specimens, have been described previously (9). CDC recommendations for Zika Virus tTesting of serum and other clinical specimens remain unchanged at this time (8). CDC will continue to review and update guidance for Zika Virus tTesting as new data become available.
  
  Suggested citation for this article: Interim Guidance for Zika Virus Testing of Urine — United States, 2016. MMWR Morb Mortal Wkly Rep 2016;65. DOI: http://dx.doi.org/10.15585/mmwr.mm6518e1.
  
  mm6518e1.pdf
  
  PMID: 27171368
  
  
• Subjects:
  Nucleic Acid Amplification Techniques Reverse Transcriptase Polymerase Chain Reaction Urinalysis Zika Virus Infection/Diagnosis Zika Virus Infection/urine
• Source:
  MMWR: Morbidity and Mortality Weekly Report 2016; v. 65, no. 18
• Series:
  Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
• DOI:
  http://dx.doi.org/10.15585/mmwr.mm6518e1
• ISSN:
  0149-2195 (print) ; 1545-861X (digital)
• Pubmed ID:
  27171368
• Document Type:
  Journal Article
• Genre:
  Guideline
• Place as Subject:
  United States
• Pages in Document:
  1 pdf page
• Volume:
  65
• Issue:
  18
• Collection(s):
  Morbidity and Mortality Weekly Report (MMWR)
• Main Document Checksum:
  urn:sha-512:0066f430885b58fe84523de6566490b0b8c611a5c21c37a65a9d09ea82a698699efb7fa88ce88321bcd170cd11106e5f9a571075ab6434e6711470829de2c508
• Download URL:
  https://stacks.cdc.gov/view/cdc/39409/cdc_39409_DS1.pdf
• File Type:
  [PDF - 58.54 KB ]